Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 167

1.

Reprogramming the antigen specificity of B cells using genome-editing technologies.

Voss JE, Gonzalez-Martin A, Andrabi R, Fuller RP, Murrell B, McCoy LE, Porter K, Huang D, Li W, Sok D, Le K, Briney B, Chateau M, Rogers G, Hangartner L, Feeney AJ, Nemazee D, Cannon P, Burton DR.

Elife. 2019 Jan 17;8. pii: e42995. doi: 10.7554/eLife.42995.

2.

Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis.

Cortes J, Calvo V, Ramírez-Merino N, O'Shaughnessy J, Brufsky A, Robert N, Vidal M, Muñoz E, Perez J, Dawood S, Saura C, Di Cosimo S, González-Martín A, Bellet M, Silva OE, Miles D, Llombart A, Baselga J.

Ann Oncol. 2019 Jan 9. doi: 10.1093/annonc/mdy535. [Epub ahead of print] No abstract available.

PMID:
30624662
3.

Cost-utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain.

Moya-Alarcón C, González-Domínguez A, Simon S, Pérez-Román I, González-Martín A, Bayo-Lozano E, Sánchez-Heras AB.

Clin Transl Oncol. 2019 Jan 8. doi: 10.1007/s12094-018-02026-2. [Epub ahead of print]

PMID:
30617925
4.

Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer.

González Martín A, Oza AM, Embleton AC, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Bertrand MA, Beale P, Cervantes A, Kent E, Kaplan RS, Parmar MKB, Scotto N, Perren TJ; ICON7 investigators.

Gynecol Oncol. 2019 Jan;152(1):53-60. doi: 10.1016/j.ygyno.2018.08.036. Epub 2018 Nov 16.

5.

Hernias at the extraction incision after laparoscopic colon and rectal resection: Influence of incision location and use of prophylactic mesh.

Pereira JA, Pera M, López-Cano M, Pascual M, Alonso S, Salvans S, Jiménez-Toscano M, González-Martín A, Grande-Posa L.

Cir Esp. 2019 Jan;97(1):20-26. doi: 10.1016/j.ciresp.2018.08.002. Epub 2018 Oct 19. English, Spanish.

PMID:
30348508
6.

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P.

N Engl J Med. 2018 Dec 27;379(26):2495-2505. doi: 10.1056/NEJMoa1810858. Epub 2018 Oct 21.

PMID:
30345884
7.

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C; ESMO Guidelines Working Group.

Ann Oncol. 2018 Oct 1;29(Supplement_4):iv259. doi: 10.1093/annonc/mdy157. No abstract available.

PMID:
30285216
8.

Is there a role for HIPEC in ovarian cancer?

Harter P, du Bois A, Sehouli J, Mahner S, Vergote I, Chiva L, Gonzalez-Martin A, Fotopoulou C.

Arch Gynecol Obstet. 2018 Nov;298(5):859-860. doi: 10.1007/s00404-018-4908-0.

PMID:
30232581
9.

Safety and dose modification for patients receiving niraparib.

Berek JS, Matulonis UA, Peen U, Ghatage P, Mahner S, Redondo A, Lesoin A, Colombo N, Vergote I, Rosengarten O, Ledermann J, Pineda M, Ellard S, Sehouli J, Gonzalez-Martin A, Berton-Rigaud D, Madry R, Reinthaller A, Hazard S, Guo W, Mirza MR.

Ann Oncol. 2018 Aug 13. doi: 10.1093/annonc/mdy255. [Epub ahead of print] No abstract available.

PMID:
30107447
10.

Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer.

Moore KN, O'Malley DM, Vergote I, Martin LP, Gonzalez-Martin A, Malek K, Birrer MJ.

Gynecol Oncol. 2018 Oct;151(1):46-52. doi: 10.1016/j.ygyno.2018.07.017. Epub 2018 Aug 6.

11.

HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer?

Fotopoulou C, Sehouli J, Mahner S, Harter P, Van Nieuwenhuysen E, Gonzalez-Martin A, Vergote I, Chiva L, Du Bois A.

Ann Oncol. 2018 Aug 1;29(8):1610-1613. doi: 10.1093/annonc/mdy198. No abstract available.

PMID:
29873689
12.

[Effectiveness of an intervention strategy in the biosimilar glargine prescription pattern in primary care].

Saborido-Cansino C, Santos-Ramos B, Carmona-Saucedo C, Rodríguez-Romero MV, González-Martín A, Palma-Amaro A, Rojas-Lucena IM, Almeida-González C, Sánchez-Fidalgo S.

Aten Primaria. 2018 May 31. pii: S0212-6567(17)30521-8. doi: 10.1016/j.aprim.2018.02.012. [Epub ahead of print] Spanish.

13.

Safety and dose modification for patients receiving niraparib.

Berek JS, Matulonis UA, Peen U, Ghatage P, Mahner S, Redondo A, Lesoin A, Colombo N, Vergote I, Rosengarten O, Ledermann J, Pineda M, Ellard S, Sehouli J, Gonzalez-Martin A, Berton-Rigaud D, Madry R, Reinthaller A, Hazard S, Guo W, Mirza MR.

Ann Oncol. 2018 Aug 1;29(8):1784-1792. doi: 10.1093/annonc/mdy181.

PMID:
29767688
14.

Reevaluation of 'endocostal ossifications' on the Kebara 2 Neanderthal ribs.

García-Martínez D, Campo Martín M, González Martín A, Cambra-Moo Ó, Barash A, Bastir M.

J Hum Evol. 2018 Sep;122:33-37. doi: 10.1016/j.jhevol.2018.04.011. Epub 2018 May 10. No abstract available.

PMID:
29754744
15.

Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct 1;29(Supplement_4):iv262. doi: 10.1093/annonc/mdy160. No abstract available.

PMID:
29741577
16.

[Recommendations for biomarker testing in epithelial ovarian cancer. A national consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology].

Oaknin A, Guarch R, Barretina P, Hardisson D, González-Martín A, Matías-Guiu X, Pérez-Fidalgo A, Vieites B, Romero I, Palacios J.

Rev Esp Patol. 2018 Apr - Jun;51(2):84-96. doi: 10.1016/j.patol.2017.11.002. Epub 2018 Jan 17. Spanish.

PMID:
29602379
17.

Comment upon "Basilar portion porosity: A pathological lesion possibly associated with infantile scurvy".

González Martín A, Robles Rodríguez FJ, Cambra-Moo O, Rascón Pérez J, Campo Martín M.

Int J Paleopathol. 2018 Mar;20:114-115. doi: 10.1016/j.ijpp.2017.09.003. Epub 2017 Oct 10. No abstract available.

PMID:
29496209
18.

Correction to: SEOM clinical guidelines for endometrial cancer (2017).

Santaballa A, Matías-Guiu X, Redondo A, Carballo N, Gil M, Gómez C, Gorostidi M, Gutierrez M, Gónzalez-Martín A.

Clin Transl Oncol. 2018 Apr;20(4):559-560. doi: 10.1007/s12094-018-1842-3.

PMID:
29417438
19.

SEOM clinical guidelines for endometrial cancer (2017).

Santaballa A, Matías-Guiu X, Redondo A, Carballo N, Gil M, Gómez C, Gorostidi M, Gutierrez M, Gónzalez-Martín A.

Clin Transl Oncol. 2018 Jan;20(1):29-37. doi: 10.1007/s12094-017-1809-9. Epub 2017 Dec 13. Erratum in: Clin Transl Oncol. 2018 Feb 7;:.

20.

Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference.

Bookman MA, Okamoto A, Stuart G, Yanaihara N, Aoki D, Bacon M, Fujiwara K, González-Martín A, Harter P, Kim JW, Ledermann J, Pujade-Lauraine E, Quinn M, Ochiai K; 5th Ovarian Cancer Consensus Conference.

Ann Oncol. 2017 Nov 1;28(suppl_8):viii30-viii35. doi: 10.1093/annonc/mdx449. Review.

21.

OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer.

Provencher DM, Gallagher CJ, Parulekar WR, Ledermann JA, Armstrong DK, Brundage M, Gourley C, Romero I, Gonzalez-Martin A, Feeney M, Bessette P, Hall M, Weberpals JI, Hall G, Lau SK, Gauthier P, Fung-Kee-Fung M, Eisenhauer EA, Winch C, Tu D, MacKay HJ.

Ann Oncol. 2018 Feb 1;29(2):431-438. doi: 10.1093/annonc/mdx754.

PMID:
29186319
22.

Evaluation of the contribution of D9S1120 to anthropological studies in Native American populations.

Aguilar-Velázquez JA, Martínez-Sevilla VM, Sosa-Macías M, González-Martin A, Muñoz-Valle JF, Rangel-Villalobos H.

Homo. 2017 Dec;68(6):440-451. doi: 10.1016/j.jchb.2017.10.003. Epub 2017 Oct 26.

PMID:
29175060
23.

Update on relapsed ovarian cancer treatment: from new consensus to daily clinical practice.

González-Martín A.

Future Oncol. 2017 Oct;13(23s):3-9. doi: 10.2217/fon-2017-0316. Epub 2017 Oct 11.

PMID:
29020819
24.

Erratum to: Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology.

Oaknin A, Guarch R, Barretina P, Hardisson D, González-Martín A, Matías-Guiu X, Pérez-Fidalgo A, Vieites B, Romero I, Palacios J.

Clin Transl Oncol. 2018 Mar;20(3):424. doi: 10.1007/s12094-017-1746-7. No abstract available.

PMID:
28933007
25.

Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N; ESMO Guidelines Committee.

Ann Oncol. 2017 Jul 1;28(suppl_4):iv72-iv83. doi: 10.1093/annonc/mdx220. No abstract available.

PMID:
28881916
26.

Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology.

Oaknin A, Guarch R, Barretina P, Hardisson D, González-Martín A, Matías-Guiu X, Pérez-Fidalgo A, Vieites B, Romero I, Palacios J.

Clin Transl Oncol. 2018 Mar;20(3):274-285. doi: 10.1007/s12094-017-1719-x. Epub 2017 Aug 16. Erratum in: Clin Transl Oncol. 2017 Sep 20;:.

PMID:
28815456
27.

Forensic efficiency parameters of the Investigator Argus X-12 kit in women from two Mestizo and seven Amerindian populations from Mexico.

Cortés-Trujillo I, Ramos-González B, Salas-Salas O, Zuñiga-Chiquette F, Zetina Hernández A, Martínez-Cortés G, Ruiz-Hernández M, González-Martín A, Ferragut JF, Rangel-Villalobos H.

Leg Med (Tokyo). 2017 May;26:62-64. doi: 10.1016/j.legalmed.2017.03.006. Epub 2017 Mar 24.

PMID:
28549550
28.

Critically short telomeres and toxicity of chemotherapy in early breast cancer.

Quintela-Fandino M, Soberon N, Lluch A, Manso L, Calvo I, Cortes J, Moreno-Antón F, Gil-Gil M, Martinez-Jánez N, Gonzalez-Martin A, Adrover E, de Andres R, Viñas G, Llombart-Cussac A, Alba E, Mouron S, Guerra J, Bermejo B, Zamora E, García-Saenz JA, Simon SP, Carrasco E, Escudero MJ, Campo R, Colomer R, Blasco MA.

Oncotarget. 2017 Mar 28;8(13):21472-21482. doi: 10.18632/oncotarget.15592.

29.

Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer.

Poveda A, Del Campo JM, Ray-Coquard I, Alexandre J, Provansal M, Guerra Alía EM, Casado A, Gonzalez-Martin A, Fernández C, Rodriguez I, Soto A, Kahatt C, Fernández Teruel C, Galmarini CM, Pérez de la Haza A, Bohan P, Berton-Rigaud D.

Ann Oncol. 2017 Jun 1;28(6):1280-1287. doi: 10.1093/annonc/mdx111.

30.

Differential Sensitivity of Target Genes to Translational Repression by miR-17~92.

Jin HY, Oda H, Chen P, Yang C, Zhou X, Kang SG, Valentine E, Kefauver JM, Liao L, Zhang Y, Gonzalez-Martin A, Shepherd J, Morgan GJ, Mondala TS, Head SR, Kim PH, Xiao N, Fu G, Liu WH, Han J, Williamson JR, Xiao C.

PLoS Genet. 2017 Feb 27;13(2):e1006623. doi: 10.1371/journal.pgen.1006623. eCollection 2017 Feb.

31.

High Power Density Electrochemical Thermocells for Inexpensively Harvesting Low-Grade Thermal Energy.

Zhang L, Kim T, Li N, Kang TJ, Chen J, Pringle JM, Zhang M, Kazim AH, Fang S, Haines C, Al-Masri D, Cola BA, Razal JM, Di J, Beirne S, MacFarlane DR, Gonzalez-Martin A, Mathew S, Kim YH, Wallace G, Baughman RH.

Adv Mater. 2017 Mar;29(12). doi: 10.1002/adma.201605652. Epub 2017 Jan 25.

PMID:
28121372
32.

Advanced stage yolk sac ovarian tumour: clinical approach with cytoreductive surgery upfront.

Pimentel I, González Martin A, Bratos R, Marquez R, Toledo G, Chiva L.

Eur J Gynaecol Oncol. 2017;38(2):311-313.

PMID:
29953803
33.

Progress in PARP inhibitors beyond BRCA mutant recurrent ovarian cancer?

González Martín A.

Lancet Oncol. 2017 Jan;18(1):8-9. doi: 10.1016/S1470-2045(16)30621-0. Epub 2016 Nov 29. No abstract available.

PMID:
27908593
34.

SEOM Clinical Guideline in ovarian cancer (2016).

Santaballa A, Barretina P, Casado A, García Y, González-Martín A, Guerra E, Laínez N, Martinez J, Redondo A, Romero I.

Clin Transl Oncol. 2016 Dec;18(12):1206-1212. Epub 2016 Nov 30.

35.

Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial.

Sorio R, Roemer-Becuwe C, Hilpert F, Gibbs E, García Y, Kaern J, Huizing M, Witteveen P, Zagouri F, Coeffic D, Lück HJ, González-Martín A, Kristensen G, Levaché CB, Lee CK, Gebski V, Pujade-Lauraine E; AURELIA Investigators.

Gynecol Oncol. 2017 Jan;144(1):65-71. doi: 10.1016/j.ygyno.2016.11.006. Epub 2016 Nov 18.

PMID:
27871723
36.

Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients.

Vergote I, Banerjee S, Gerdes AM, van Asperen C, Marth C, Vaz F, Ray-Coquard I, Stoppa-Lyonnet D, Gonzalez-Martin A, Sehouli J, Colombo N.

Eur J Cancer. 2016 Dec;69:127-134. doi: 10.1016/j.ejca.2016.10.006. Epub 2016 Nov 4. Review.

PMID:
27821315
37.
38.

Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).

Sehouli J, Chekerov R, Reinthaller A, Richter R, Gonzalez-Martin A, Harter P, Woopen H, Petru E, Hanker LC, Keil E, Wimberger P, Klare P, Kurzeder C, Hilpert F, Belau AK, Zeimet A, Bover-Barcelo I, Canzler U, Mahner S, Meier W.

Ann Oncol. 2016 Dec;27(12):2236-2241. doi: 10.1093/annonc/mdw418. Epub 2016 Oct 26.

PMID:
27789470
39.

Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer.

Vrdoljak E, Marschner N, Zielinski C, Gligorov J, Cortes J, Puglisi F, Aapro M, Fallowfield L, Fontana A, Inbar M, Kahan Z, Welt A, Lévy C, Brain E, Pivot X, Putzu C, González Martín A, de Ducla S, Easton V, von Minckwitz G.

Ann Oncol. 2016 Nov;27(11):2046-2052. Epub 2016 Aug 8.

PMID:
27502725
40.

Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study.

Oza AM, Selle F, Davidenko I, Korach J, Mendiola C, Pautier P, Chmielowska E, Bamias A, DeCensi A, Zvirbule Z, González-Martín A, Hegg R, Joly F, Zamagni C, Gadducci A, Martin N, Robb S, Colombo N.

Int J Gynecol Cancer. 2017 Jan;27(1):50-58. doi: 10.1097/IGC.0000000000000836.

41.

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Mądry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA; ENGOT-OV16/NOVA Investigators.

N Engl J Med. 2016 Dec 1;375(22):2154-2164. Epub 2016 Oct 7.

42.

18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial.

Quintela-Fandino M, Lluch A, Manso L, Calvo I, Cortes J, García-Saenz JA, Gil-Gil M, Martinez-Jánez N, Gonzalez-Martin A, Adrover E, de Andres R, Viñas G, Llombart-Cussac A, Alba E, Guerra J, Bermejo B, Zamora E, Moreno-Anton F, Pernas Simon S, Carrato A, Lopez-Alonso A, Escudero MJ, Campo R, Carrasco E, Palacios J, Mulero F, Colomer R.

Clin Cancer Res. 2017 Mar 15;23(6):1432-1441. doi: 10.1158/1078-0432.CCR-16-0738. Epub 2016 Sep 1.

43.

Geometric morphometrics reveals restrictions on the shape of the female os coxae.

Candelas González N, Rascón Pérez J, Chamero B, Cambra-Moo O, González Martín A.

J Anat. 2017 Jan;230(1):66-74. doi: 10.1111/joa.12528. Epub 2016 Aug 3.

44.

A miR-155-Peli1-c-Rel pathway controls the generation and function of T follicular helper cells.

Liu WH, Kang SG, Huang Z, Wu CJ, Jin HY, Maine CJ, Liu Y, Shepherd J, Sabouri-Ghomi M, Gonzalez-Martin A, Xu S, Hoffmann A, Zheng Y, Lu LF, Xiao N, Fu G, Xiao C.

J Exp Med. 2016 Aug 22;213(9):1901-19. doi: 10.1084/jem.20160204. Epub 2016 Aug 1.

45.

Regulation of B-cell development and tolerance by different members of the miR-17∼92 family microRNAs.

Lai M, Gonzalez-Martin A, Cooper AB, Oda H, Jin HY, Shepherd J, He L, Zhu J, Nemazee D, Xiao C.

Nat Commun. 2016 Aug 2;7:12207. doi: 10.1038/ncomms12207.

46.

Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer.

Hergueta-Redondo M, Sarrio D, Molina-Crespo Á, Vicario R, Bernadó-Morales C, Martínez L, Rojo-Sebastián A, Serra-Musach J, Mota A, Martínez-Ramírez Á, Castilla MÁ, González-Martin A, Pernas S, Cano A, Cortes J, Nuciforo PG, Peg V, Palacios J, Pujana MÁ, Arribas J, Moreno-Bueno G.

Oncotarget. 2016 Aug 30;7(35):56295-56308. doi: 10.18632/oncotarget.10787.

47.

Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer.

Kim SB, Wildiers H, Krop IE, Smitt M, Yu R, Lysbet de Haas S, Gonzalez-Martin A.

Int J Cancer. 2016 Nov 15;139(10):2336-42. doi: 10.1002/ijc.30276. Epub 2016 Jul 26.

48.

FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited.

Ataseven B, Chiva LM, Harter P, Gonzalez-Martin A, du Bois A.

Gynecol Oncol. 2016 Sep;142(3):597-607. doi: 10.1016/j.ygyno.2016.06.013. Epub 2016 Jun 19. Review.

PMID:
27335253
49.

The MicroRNA-183-96-182 Cluster Promotes T Helper 17 Cell Pathogenicity by Negatively Regulating Transcription Factor Foxo1 Expression.

Ichiyama K, Gonzalez-Martin A, Kim BS, Jin HY, Jin W, Xu W, Sabouri-Ghomi M, Xu S, Zheng P, Xiao C, Dong C.

Immunity. 2016 Jun 21;44(6):1284-98. doi: 10.1016/j.immuni.2016.05.015.

50.

Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE).

Kurzeder C, Bover I, Marmé F, Rau J, Pautier P, Colombo N, Lorusso D, Ottevanger P, Bjurberg M, Marth C, Barretina-Ginesta P, Vergote I, Floquet A, Del Campo JM, Mahner S, Bastière-Truchot L, Martin N, Oestergaard MZ, Kiermaier A, Schade-Brittinger C, Polleis S, du Bois A, Gonzalez-Martin A.

J Clin Oncol. 2016 Jul 20;34(21):2516-25. doi: 10.1200/JCO.2015.66.0787. Epub 2016 Jun 6.

PMID:
27269942

Supplemental Content

Loading ...
Support Center